Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111733 | 0.92 | SLC6A4 (0.45) | SLC6A4KDM4EALDH1A1SCN9AKDM5C | |
| SCHEMBL5117800 | 0.91 | SLC6A4 (0.42) | SLC6A4KDM4EALDH1A1SCN9AWNT1 | |
| SCHEMBL5110646 | 0.91 | SLC6A4 (0.46) | SLC6A4KDM4EALDH1A1HPGDKDM5C | |
| SCHEMBL14276265 | 0.90 | PIK3CA (0.40) | SLC6A4KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5114026 | 0.84 | MET (0.37) | KDM4EALDH1A1KMOTSHRCCR2 | |
| SCHEMBL5125532 | 0.83 | PPARG (0.48) | KDM4EALDH1A1HPGDPPARGCCR2 | |
| SCHEMBL5124452 | 0.83 | PPARG (0.40) | KDM4EALDH1A1HPGDPPARGCCR2 | |
| SCHEMBL5117903 | 0.83 | PPARG (0.39) | KDM4EALDH1A1HPGDPPARGCCR2 | |
| SCHEMBL5685433 | 0.82 | GSK3A (0.47) | — | |
| SCHEMBL5685427 | 0.81 | SRC (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | claimed |
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| US-7078419-B2 | N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040186114-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186114-A1 | Cytokine inhibitors | IL1A, IL1B, IL1R1 | SLC6A4 4862/4885CXCR4 363/4885KDM4E 3470/4885 |
| US-20060235017-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1R1 | SLC6A4 4868/4885CXCR4 448/4885KDM4E 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.